Sugi Predict

Sugi Predict / Compounds / SCHEMBL3309908

SCHEMBL3309908

SCHEMBL3309908

CCCCC(=O)NC1CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.65
▸ ALDH1A1 P00352 1/20 0.65
▸ MAPT P10636 1/20 0.65
▸ HPGD P15428 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ GNAI3 P08754 1/20 0.64
▸ GNAO1 P09471 1/20 0.64
▸ GNAI1 P63096 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ SMYD3 Q9H7B4 1/20 0.54
▸ CNR2 P34972 7/20 0.54
▸ CNR1 P21554 6/20 0.54
▸ HDAC3 O15379 2/20 0.53
▸ HDAC1 Q13547 2/20 0.53
▸ HDAC2 Q92769 2/20 0.53
▸ HDAC10 Q969S8 2/20 0.53
▸ HDAC11 Q96DB2 2/20 0.53
▸ HDAC8 Q9BY41 2/20 0.53
▸ HDAC6 Q9UBN7 2/20 0.53
▸ NCOR2 Q9Y618 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3551415 0.94 GNAI3 (0.72) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL1457137 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL1234276 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL4674083 0.92 SMN1; SMN2 (0.77) MEN1ALDH1A1MAPTHPGDKMT2A
Hexadecanoic Acid Cyclopropylamide SCHEMBL1456457 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL8361102 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL28340804 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL11571826 0.92 GNAI3 (0.75) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL23989211 0.90 SMN1; SMN2 (0.74) ALDH1A1HPGDGNAI3GNAO1GNAI1
SCHEMBL7494872 0.90 SMN1; SMN2 (0.74) ALDH1A1HPGDGNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013754-B1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2024-07-24 — — EP claimed
US-12371434-B2 MLL1 inhibitors and anti-cancer agents CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2025-07-29 — — US disclosed
CN-115710298-B Cholic acid derivative, preparation method thereof and application of cholic acid derivative as TGR5 allosteric agonist 常州大学 2024-10-01 — — CN disclosed
CN-118724999-A Synthesis of cholic acid derivative and application of cholic acid derivative as TGR5 allosteric agonist 常州大学 2024-10-01 — — CN disclosed
WO-2023168974-A1 CHOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF AS TGR5 ALLOSTERIC AGONIST 常州大学 2023-09-14 — — WO disclosed
EP-3820869-B1 SPIROCHROMANE DERIVATIVES RICHTER GEDEON NYRT (HU) 2023-08-30 — — EP disclosed
US-20230121768-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-04-20 — — US disclosed
CN-115710298-A Cholic acid derivatives, their preparation and use as TGR5 allosteric agonists 常州大学 2023-02-24 — — CN disclosed
US-20210330650-A1 SPIROCHROMANE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2021-10-28 — — US disclosed
EP-3820865-A1 THIADIAZINE DERIVATIVES Richter Gedeon Nyrt. (HU) 2021-05-19 — — EP disclosed
US-9669095-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2017-06-06 — — US disclosed
WO-2015031381-A1 CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C ENANTA PHARMACEUTICALS, INC. (US) 2015-03-05 — — WO disclosed
CN-101815512-B Cyclopropyl aryl amide derivatives and uses thereof HOFFMANN LA ROCHE 2013-04-24 — — CN disclosed
CN-101815512-B Cyclopropyl aryl amide derivatives and uses thereof HOFFMANN LA ROCHE 2013-04-24 — — CN disclosed
CN-101815512-A cyclopropyl aryl amide derivatives and uses thereof HOFFMANN LA ROCHE 2010-08-25 — — CN disclosed
CN-101815512-A cyclopropyl aryl amide derivatives and uses thereof HOFFMANN LA ROCHE 2010-08-25 — — CN disclosed
US-7723391-B2 Cyclopropyl aryl amide derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2010-05-25 — — US disclosed
US-20090093525-A1 Cyclopropyl aryl amide derivatives and uses thereof ROCHE PALO ALTO LLC 2009-04-09 — — US disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 — — US disclosed
CN-101180266-A Alpha ketoamide compounds as cysteine protease inhibitors APPLERA CORP (US) 2008-05-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371434-B2 MLL1 inhibitors and anti-cancer agents MLLT1, BMI1, DOT1L MEN1 527/4885ALDH1A1 1136/4885MAPT 3174/4885
US-20210330650-A1 SPIROCHROMANE DERIVATIVES CHRNA7, CHRM3, ADRB3 MEN1 1521/4885ALDH1A1 791/4885MAPT 1498/4885
US-20230121768-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS MLLT1, BMI1, DOT1L MEN1 527/4885ALDH1A1 1136/4885MAPT 3174/4885
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 MEN1 4274/4885ALDH1A1 2269/4885MAPT 1623/4885
US-20090093525-A1 Cyclopropyl aryl amide derivatives and uses thereof AR, ADRA2A, ADRA1A MEN1 2297/4885ALDH1A1 244/4885MAPT 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.